Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913535 | 0.83 | MEN1 (0.56) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL19273403 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL2073087 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL87424 | 0.79 | SPHK2 (0.65) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL12809838 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL4446395 | 0.78 | ALOX12 (0.50) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL12099840 | 0.78 | MEN1 (0.50) | MEN1KMT2ATDP1DPP7MAOA | |
| Hydrochloric Acid SCHEMBL8520812 | 0.78 | SPHK2 (0.63) | MEN1KMT2ATDP1DPP7MAPT | |
| SCHEMBL27641175 | 0.78 | MEN1 (0.50) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL12099838 | 0.78 | MEN1 (0.50) | MEN1KMT2ATDP1DPP7MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| CN-105916499-B | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2020-02-18 | — | — | CN | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| EP-3096751-A1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2016-11-30 | — | — | EP | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | MEN1 811/4885KMT2A 1237/4885TDP1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.